Condition: Cancer Related Cognitive Decline · Non-metastatic Breast Cancer · Sponsor: Georgetown University
This is a pilot study to evaluate the effects of azeliragon to decrease cardiac toxicity from chemotherapy and the safety of azelirgaon when given with chemotherapy. The Investigators hypothesize that there will be no significant interaction with Azeliragon and chemotherapy and that targeting the RAGE pathway will decrease anthracycline related cardiotoxicity and chemotherapy related cognitive decline.
This description comes directly from the study's public registry record.
Lana Kheir · 202-687-9016 · lk814@georgetown.edu
Always discuss trial participation with your own doctor first.
| Georgetown Lombardi Comprehensive Cancer Center | Washington D.C., District of Columbia, United States | Recruiting |
| Medstar Washington Hospital Center | Washington D.C., District of Columbia, United States | Recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack, New Jersey, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05256745